Abemaciclib, another CDK4/6 inhibitor in a dose and schedule of 200 mg by mouth twice daily continuously, resulted in a median PFS of 30.4 (95% CI, 28.9-NE) weeks and PFS rate at 12 weeks of 76% (95% CI, 57–90%) in patients with advanced DDLPS in a Phase 2 study [62]. The gene discussed is CDK4; the disease is dedifferentiated liposarcoma.